RealFeedApp Janet Freeman-Daily controls lung cancer with crizotinib
A patient with a rare ROS1 mutation survived 15 years on crizotinib, yet the treatment could not prevent cancer progression in her peers.
- Field
- drugs and trials
- What they did
- Researchers and a patient described how the drug crizotinib allowed her to control lung cancer for 15 years, despite it failing to save other patients with the same mutation.
- Why it matters
- This is important for understanding why some patients with the rare ROS1 mutation survive for decades while others, treated later, do not experience the same success.
#crizotinib#lung cancer#clinical trial#ros1 mutation
